Archived: 11th Winter Conference
on Medicinal & Bioorganic Chemistry
January 20th - 24th 2013
Steamboat Springs Resort, Colorado
Agenda
Sunday, January 20th 2013
Innovations in Drug Candidate Development
Program Chair: Trevor Laird, Scientific Update
An Overview of Drug Candidate Development: Industrial Case Studies
Development of a Manufacturing Route for the HCV Protease Inhibitor Faldaprevir
Strategies for Chirality Control on Multi-Kilogram Scale: Development of an Enantioselctive Synthesis of Filibuvir
Early Process Research: Developing a Synthetic Strategy for PI3kd Inhibitors
Monday, January 21st 2013
Cancer Cell Metabolism and Opportunities for Therapeutic Intervention
Program Chair: Tim Burkholder, Eli Lilly & Co
Targeting Metabolic Reprogramming for Cancer
New Strategies for Impacting Glutamine Metabolism in Cancer Cells
Pyruvate Kinase M2 Activators Induce Tetramerization and Reduce Tumor Size in Mouse Xenograft Models
Discovery and Characterization of Mutant IDH Inhibitors for the Treatment of Cancer
Structure-based Identification of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors
Design of Optimized Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors
Neglected Infectious Diseases and Parasitic Infections
Program Chair: Richard Lee & Kip Guy, St Judes Children Research Hospital
The Discovery, Optimisation, and Mode of Action of Spiroindolone Antimalarials
The Discovery and Optimization of Novel Anti-Malarial Agents Derived from Phenotypic Screening
Rational Design of Antibiotics for Tuberculosis that Target Biotin Metabolism
Syntheses and Evaluation of New Anti-tuberculosis Agents Inspired by Studies of Mycobacterial Iron Assimilation
Tuesday, January 22nd 2013
Academic Session | Indiana University
Program Chair: Mike VanNieuwenhze, Indiana University
Challenges in Glycan Synthesis
The Quest for Affordable, Fully Synthetic Artemisinin
Chemical Biotechnology Applied to Endocrine Hormones
Chemoselective Enrichment for Natural Products Discovery
Structural Insights into Targeted Drug Delivery via the Human Folate Receptors
Frontiers in Synthesis
Program Chair: Victor Snieckus, Queen’s University
Base Metal Catalysis for Organic Synthesis
Inhibitors of 5-HT2CR Protein:Protein Interactions for Stimulant Pharmacotherapy
Facilitation of Scale-Up of Novel Oncology Candidates through Early Route Optimisation – Risk and Rewards
Advances in Ni- and Fe-Catalyzed Cycloaddition Chemistry
Wednesday, January 23rd 2013
New Frontiers in Medicinal Chemistry
Program Chair: Philippe Nantermet, Merck Research Laboratories
Covalent Inhibitors in Drug Design
Recent Advances in siRNA Delivery
The Impact of Oxetane and Bicyclo[1.1.1]pentane Motifs on Biopharmaceutical Properties
Drug Discovery and Optimization using Computer Generated Molecules with Predicted Potencies
Phenotypic Drug Discovery of Novel Anti-Angiogenics
Open Session
Program Chair: Matt Hayward, Pfizer
Studies Leading to the Clinical Candidate EPZ-5676, a DOT1L Inhibitor for the Treatment of MLL-rearranged Leukemia
Discovery of a Series of Brain-Penetrant Kynurenine Aminotransferase II Inhibitors for the Treatment of Schizophrenia
Discovery of HCV Polymerase Inhibitors ABT-333 and ABT-072: Components of an IFN-sparing Drug Regimen
Development and Application of a Highly Selective Histone Deacetylase 8 Inhibitor
KEYNOTE PRESENTATION
Program Chair: Dr Philippe Nantermet, Merck
Imagine: Pharma Be Fractal
Thursday, January 24th 2013
Emerging Therapies for Hepatitis C
Program Chair: John A. McCauley, Merck Research Laboratories
Discovery of HCV NS5A Replication Complex Inhibitors
Optimization of HCV NS5B Thumb Site II Inhibitors for Use in Interferon-Free Regimens
Discovery of a Novel Allosteric Mechanism for the Regulation of HCV NS3 Protein using Fragment Screening and Structure-Based Design
The Discovery of a Potent and Selective Irreversible HCV Protease Inhibitor
Treatment of Liquid Disorders: Metabolic Syndrome and Beyond
Program Chair: Lance Pfeifer, Eli Lilly & Co
DGAT1 Inhibitors for Suppression of Postprandial Triglycerides
The Discovery and Development of Anacetrapib, a Potent and Orally Active CETP Inhibitor
The Discovery and Optimization of a Novel Series of LPA Receptor Antagonists with Efficacy in Multiple Mouse Models of Fibrosis
Development of a Potent, Selective, and Orally Bioavailable mPGES-1 Inhibitor based on a Benzoxazole Template for the Treatment of Osteoarthritis Pain and Inflammation
Media Sponsors
